Skip to content
Douglas API
Just another WordPress site
Author:
Victoria Hayward
Douglas Pharmaceuticals secures US licensing deal to treat high grade cervical dysplasia
Formation of Clinical Advisory Board for Lead Program R-107
Clinicians China licenced to HTDK Pharmaceuticals
New Zealand’s largest medical R&D facility opens in West Auckland